Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalties
Biotech
Xoma adds another struggling biotech to its buyout roster
After Generation Bio telegraphed major layoffs this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold.
Fraiser Kansteiner
Dec 16, 2025 11:00am
Nanobiotix finds new way to source cash from J&J-partnered drug
Oct 31, 2025 6:05am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Boehringer digs in on ADCs with $991M AimedBio licensing accord
Oct 15, 2025 10:05am
Anaptys plans to split into 2 businesses
Sep 30, 2025 9:35am
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Jun 24, 2025 9:00am
